Vectus Biosystems Overview
- Year Founded
-
2005
- Status
-
Public
- Stock Symbol
-
VBS
- Share Price
-
$0.03
- (As of Tuesday Closing)
Vectus Biosystems General Information
Description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including cardio, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
Contact Information
Website
www.vectusbiosystems.com.auCorporate Office
- Unit 5, Ground Floor
- 26-34 Dunning Avenue
- Rosebery, New South Wales 2018
- Australia
Corporate Office
- Unit 5, Ground Floor
- 26-34 Dunning Avenue
- Rosebery, New South Wales 2018
- Australia
Vectus Biosystems Timeline
Vectus Biosystems Stock Performance
As of 17-Nov-2026, Vectus Biosystems’s stock price is $0.03. Its current market cap is $2.09M with 62.2M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.03 | $0.04 | $0.03 - $0.15 | $2.09M | 62.2M | 52.8K |
Vectus Biosystems Financials Summary
As of 30-Sep-2026, Vectus Biosystems has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 2,705 | 5,401 | 863 | 1,382 |
| EBITDA | 1,084 | (1,151) | (1,538) | |
| Net Income | 1,056 | (1,150) | (1,532) | |
| Total Assets | 2,627 | 511 | 1,354 | |
| Total Debt | 376 | 131 | 19 |
Vectus Biosystems Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vectus Biosystems Patents
Vectus Biosystems Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2016903799-A0 | Compositions for the treatment of hypertension and/or fibrosis | Inactive | 21-Sep-2016 | ||
| AU-2016903804-A0 | Compositions for the treatment of hypertension and/or fibrosis | Inactive | 21-Sep-2016 | ||
| AU-2017329111-A1 | Compositions for the treatment of hypertension and/or fibrosis | Active | 21-Sep-2016 | ||
| AU-2017329111-B2 | Compositions for the treatment of hypertension and/or fibrosis | Active | 21-Sep-2016 | ||
| AU-2017329111-B9 | Compositions for the treatment of hypertension and/or fibrosis | Active | 21-Sep-2016 | C07D233/64 |
Vectus Biosystems ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Vectus Biosystems FAQs
-
When was Vectus Biosystems founded?
Vectus Biosystems was founded in 2005.
-
Where is Vectus Biosystems headquartered?
Vectus Biosystems is headquartered in Rosebery, Australia.
-
What industry is Vectus Biosystems in?
Vectus Biosystems’s primary industry is Drug Discovery.
-
Is Vectus Biosystems a private or public company?
Vectus Biosystems is a Public company.
-
What is Vectus Biosystems’s stock symbol?
The ticker symbol for Vectus Biosystems is VBS.
-
What is the current stock price of Vectus Biosystems?
As of 17-Nov-2026 the stock price of Vectus Biosystems is $0.03.
-
What is the current market cap of Vectus Biosystems?
The current market capitalization of Vectus Biosystems is $2.09M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process